NCT04695223

Arsenic Trioxide for Structural p53 Mutations

Targeting Structural p53 Mutations With Arsenic Trioxide for Intractable Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.

Conditions

• Arsenic Trioxide
• p53 Mutations
• Refractory Cancer
• Intractable Cancer

Interventions

Type	Name	Description
DRUG	Arsenic Trioxide	Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)

Timeline

• Start date: 2021-01-01
• Primary completion: 2021-08-31
• Completion: 2021-10-31
• First posted: 2021-01-05
• Last updated: 2021-01-06

Locations

1 site across 1 country: China